ClosedGrantWon by 109 Therapeutics, Inc.SBIR Phase I SBIR
SBIR Phase I: Novel injectable long-acting local anesthetic for postoperative pain management
National Science Foundation
Closed
NAICS 541715
Source: sbir_sttr
OverviewIntelligenceProposals
Key Details
- Posted Date
- Response Deadline
- NAICS Code
- 541715
- Source
- sbir_sttr
- Award Amount
- $255,838
- Awarded To
- 109 Therapeutics, Inc.
Description
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project develops novel pain therapeutics that can reduce or eliminate the use of opioids after surgery. Opioid-based medications are a mainstay of postopera
Key Dates
Posted:→Deadline:
Frequently Asked Questions
Is this grant still open?+
No — the response deadline for this grant has passed (August 31, 2021). Browse other active National Science Foundation opportunities on Bureauify.
How do I apply for this grant?+
Review the full solicitation documents on the source website (SAM.gov or Grants.gov), prepare your proposal per the instructions, and submit before the deadline. Use Bureauify to track the opportunity and get reminders.
Who won this grant?+
This grant was awarded to 109 Therapeutics, Inc. for $255,838. Use Bureauify to analyze this vendor's contract history and win patterns.
Intelligence
- Win probability analysis
- Competitive landscape
- Incumbent analysis
- Price-to-win estimate
- Similar awards history
Data sourced from sbir_sttr